AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-74885494/biotechnology-newswatch-genentech-actelion.html" title="Facts and information about BIOTECHNOLOGY NEWSWATCH: Genentech, Actelion heart failure drug skips beat, fails in trials.">BIOTECHNOLOGY NEWSWATCH: Genentech, Actelion heart failure drug skips beat, fails in trials.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
BIOTECHNOLOGY NEWSWATCH: Genentech, Actelion heart failure drug skips beat, fails in trials.
In Phase III trials the dual endothelin receptor antagonist Veletri (which is being developed by Actelion and Genentech) failed to alleviate dyspnea in patients with heart failure when taken with the standard therapy.
Neither did it show any significant improvement in …
Related articles from newspapers, magazines, journals, and more
-
- Vasogen initiates patient enrolment in pivotal Phase III chronic heart...
-
News wire article from: Asia Africa Intelligence Wire
July 9, 2003
700+ words
-
- FDA clears Vasogen to initiate pivotal Phase III clinical trial in chronic...
-
News wire article from: Asia Africa Intelligence Wire
November 19, 2002
700+ words
-
- GE Healthcare announces data from Phase III study of AdreView in heart...
-
News wire article from: Chemical Business Newsbase
March 31, 2009
700+ words
-
- Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III...
-
News wire article from: Europe Intelligence Wire
December 23, 2009
700+ words
-
- Vasogen announces initial results from Phase III ACCLAIM trial in chronic...
-
News wire article from: Chemical Business Newsbase
June 26, 2006
700+ words
